No Data
No Data
WuXi XDC Cayman's Profit Up 82% in 2023
WuXi XDC Cayman (HKG:2268) recorded an 82% rise in attributable profit for the year 2023 to 283.5 million yuan from 155.7 million yuan in 2022, according to the company's annual report posted on the H
[Broker Focus] Minsheng Securities indicates that Pharmaceutical Federation (02268) has drastically raised the upper limit of raw material purchase agreements and maintained a “recommended” rating
Jinwu Financial News | According to the Minsheng Securities Research Report, the Pharmaceutical Federation (02268) issued an announcement to raise the upper limit of the raw material procurement service agreement from 32.6 million yuan to 80 million yuan (+145%) in 2024, and raise the upper limit from 21.3 million yuan to 75 million yuan (+252%) in 2025. Demand for raw materials from Yao Ming Biotech has further increased, and all terms and conditions of the procurement service agreement have remained unchanged. The bank indicates that in order to meet customer needs, companies must promptly purchase relevant raw materials and make inventory reserves to ensure the normal progress of the existing XDCCRDMO project
藥明合聯:2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Yao Ming Union (02268) surged more than 5% in the afternoon, and the company achieved a further breakthrough in the ADC CRDMO business after the listing
The Zhitong Finance App learned that Yao Ming United (02268) surged by more than 5% in the afternoon. As of press release, it had risen 5.01% to HK$17.6 million, with a turnover of HK$2016.67 million. Guoxin Securities pointed out that as the ADC CRDMO leader with a global layout, Pharmaceutical Federation has established a fully integrated one-stop CRDMO platform, covering the entire ADC CRDMO service process and leading the world in comprehensive capabilities. As the company's global production capacity continues to expand and pre-IND projects continue to advance to the post-IND stage, we believe that the company's business will maintain rapid growth over the next 3 years. Tianfeng Securities, on the other hand, said that
No Data